330 related articles for article (PubMed ID: 15750032)
1. Origin, structure, and activity in vitro and in vivo of dalbavancin.
Malabarba A; Goldstein BP
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii15-20. PubMed ID: 15750032
[TBL] [Abstract][Full Text] [Related]
2. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
3. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
Dorr MB; Jabes D; Cavaleri M; Dowell J; Mosconi G; Malabarba A; White RJ; Henkel TJ
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii25-30. PubMed ID: 15750034
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
5. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
7. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
Goldstein BP; Jones RN; Fritsche TR; Biedenbach DJ
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):83-7. PubMed ID: 16458124
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin: a review for dermatologists.
Scheinfeld N
Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
[TBL] [Abstract][Full Text] [Related]
9. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
[TBL] [Abstract][Full Text] [Related]
10. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
Streit JM; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
[TBL] [Abstract][Full Text] [Related]
13. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
Mushtaq S; Warner M; Johnson AP; Livermore DM
J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
[TBL] [Abstract][Full Text] [Related]
15. Glycopeptides: Update on an old successful antibiotic class.
Pace JL; Yang G
Biochem Pharmacol; 2006 Mar; 71(7):968-80. PubMed ID: 16412985
[TBL] [Abstract][Full Text] [Related]
16. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin: a novel lipoglycopeptide antibacterial.
Pope SD; Roecker AM
Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin resistance: are there better glycopeptides coming?
Linden PK
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Streit JM; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo.
Darouiche RO; Mansouri MD
J Infect; 2005 Apr; 50(3):206-9. PubMed ID: 15780414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
